|
The ABL Advisor Deal Tables
SELECTED TRANSACTION DETAILS
Hercules Technology Growth, Alimera Sciences Close $35MM Debt Facility
|
Lenders/Participants
|
Hercules Technology Growth Capital [Lender]
|
|
Structure
|
Term Loan
|
|
Amount
|
$35.000
Million
|
|
Borrower(s)
|
Alimera Sciences, Inc.
|
|
Description
|
Term loan in the principal amount of up to $35 million. Under the agreement, Hercules is advancing $10 million to Limited and will advance the remaining $25 million in the event the U.S. Food and Drug Administration (FDA) approves ILUVIEN® on or before October 31, 2014 and certain other conditions are satisfied. The proceeds of the initial funding of $10 million under the term loan will be used to pay off an existing term loan payable to Silicon Valley Bank (SVB) and to provide additional working capital for general corporate purposes. The $25 million advance will be used to fund a $25 million milestone payment obligation that will be owed by Alimera upon FDA approval of ILUVIEN. In connection with the closing of the Hercules debt facility, Limited also terminated a $15 million working capital line of credit with SVB that had not been utilized.
|
|
Industry
|
Pharmaceutical
|
|
Location
|
GA
|
| Related Tags |
Hercules Technology Growth Capital
|
ABL Advisor
Deal Tables
2025
|
|
|
|